Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,788 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Colorectal Clear all
Completed No phase listed Observational

Study of Gut Microbiome and Colorectal Tumors

NCT03297996
View directory record Official record
Conditions
Serrated Polyp, Hyperplastic Polyp, Sessile Serrated Adenoma, Colorectal Cancer
Interventions
Mobio PowerSoil DNA Isolation Kit
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 15, 2026, 5:59 PM EDT
Suspended Phase 1Phase 2 Interventional

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

NCT05200442
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions
VS-6766/avutometinib, Cetuximab, Pill Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed No phase listed Observational

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00280761
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, 5-fluorouracil, Surgical Resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

NCT05806931
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
TAS-102, oxaliplatin, irinotecan with bevacizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

NCT00012246
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

NCT04472429
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Anal Canal
Interventions
carboplatin, paclitaxel, retifanlimab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Duarte, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Not applicable Interventional Results available

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

NCT01098422
View directory record Official record
Conditions
Colorectal Neoplasms, Liver Neoplasms
Interventions
Yttrium-90 Radioactive Resin Microspheres
Device
Lead sponsor
Tony Reid, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

NCT03551951
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Interventions
Test for circulating tumor cells, DNA alterations
Diagnostic Test
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Coordinated Endoscopic Colorectal Cancer Screening

NCT00327457
View directory record Official record
Conditions
Preventive Health Services
Interventions
Help with physician office and patient management, Tailored physician recommendation letter
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 79 Years
Enrollment
599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 15, 2026, 5:59 PM EDT
Completed No phase listed Observational

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

NCT02503696
View directory record Official record
Conditions
Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions
Stool Collection Kit
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years to 84 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
27
States / cities
Dothan, Alabama • La Jolla, California • Mission Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 15, 2026, 5:59 PM EDT
Completed No phase listed Observational

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT06973161
View directory record Official record
Conditions
Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

NCT04165031
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 1 Interventional Results available

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01285102
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting No phase listed Observational

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Bethesda, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

NCT00118261
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

NCT00686166
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, capecitabine, oxaliplatin, therapeutic surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
130
States / cities
Mobile, Alabama • Tucson, Arizona • Berkeley, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Michigan Genetic Hereditary Testing (MiGHT)

NCT05162846
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy

NCT03515356
View directory record Official record
Conditions
Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Stomach Cancer, Esophageal Cancer
Interventions
MI-Walk Intervention, Physical Activity Education Pamphlet
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

NCT02191761
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
Interventions
SM04755
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

NCT03495674
View directory record Official record
Conditions
High-Frequency Microsatellite Instability, Mismatch Repair Gene Mutation, Mutation-Negative Lynch Syndrome, Mutation-Positive Lynch Syndrome
Interventions
Exercise Intervention, Informational Intervention, Monitoring Device, Questionnaire Administration
Behavioral · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 15, 2026, 5:59 PM EDT
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions
Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 5:59 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer

NCT01198535
View directory record Official record
Conditions
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Cetuximab, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 15, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screening TO Prevent ColoRectal Cancer (STOP CRC) Among At-Risk Chinese and Korean American Primary Care Patients

NCT03481296
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Advanced Control, Culturally-Adapted Decision Support Navigation Intervention
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 15, 2026, 5:59 PM EDT